MRK

December Update: ‘Margin Of Safety’ Stocks That Trade At A Discount To Value

(via www.marginofsafetyportfolio.com)

This short article is an update of stocks that we follow in our “Margin of Safety Portfolio.” These are stocks identified to have a durable competitive advantage and, based upon our intrinsic valuation models and fundamental analysis, are trading at a substantial discount to intrinsic value.

Current trends and events
■New strategic partnerships at Microsoft;
■HP’s webOS will go open source;

Advertisement:

Finding Value And Defense In Big Pharma Stocks

(via seekingalpha.com)

ong brand names, patent protection, regulatory approvals, and economies of scale are all key factors in the development and sustainability of a competitive advantage in the drug industry.

The Margin of Safety and Impact on Investment Returns

(via www.marginofsafetyportfolio.com)

In an age when market volatility is the norm and high speed computerized trading dominates the daily volume, investors would be well advised to consider an investment principle that has served some of history’s most successful investors extremely well. And that is to buy only those stocks for which the upside is substantial and the downside risk is limited. I know, easier said than done.

Merck’s Competitive Advantage: Buy And Hold, But Sell If Necessary. MRK VRTX

(via www.marginofsafetyportfolio.com)

MRK1YR

Buy and hold has gotten a bad name since the 2008 financial crisis and subsequent recession, but it is still a viable strategy for long-term investors with patience and the ability to pick the right stocks. Finding a financially strong, undervalued company with a durable competitive advantage in its industry, and a large dividend, makes a strong buy and hold candidate.

Stocks That Trade At A Discount To Value - December Update

(via seekingalpha.com)

This short article is a bimonthly news update of stocks for value investors that we follow in our “Margin of Safety Portfolio.” These are stocks identified to have a durable competitive advantage and, based upon our intrinsic valuation models and fundamental analysis, are trading at a discount to intrinsic value

Dividend Growth Stocks: 19 Stocks Avoiding A November Freeze With Increased Dividends

(via www.dividend-growth-stocks.com)

For a dividend investor, there is not much worse than a stock that cuts or eliminates its dividend. Suddenly, the reason you purchased the stock no longer exists. Many dividend investors, myself included, have a hard and fast rule to immediately sell any stock held as income investment if it cuts its dividend.

Advertisement:

Using Magic Formula Investing to Rank any List of Stocks

(via www.magicdiligence.com)

Magic Formula Investing is a process that can be applied to any list of stocks, not just the market at large. This article shows how you can use the MFI process to find the best opportunities in a variety of scenarios.

Best Stocks for 2011 | Dividends Value

(via dividendsvalue.com)

It is a great time of year! The Christmas music, decorations, family gatherings, holiday plays and stock picks. Stock picks? Yes, ’tis the season for stock predictions! Virtually every financial writer will pen an article selecting his or her top picks for the upcoming year. I enjoy reading them and the logic behind the picks.

The best dividend payers

(via marginofsafetyinvesting.com)

Searching for the best dividend stocks in the US...starting with the entire US listed stock universe and filtering down to 18 companies that have good dividends, business performance and conservative balance sheet and valuation

10 Hedge Fund Favorites for Earnings & Dividend Yield

(via blog.ycharts.com)

If you like buying earning power at a discount, earnings yield is a good place to start. It is one of the most useful metrics available to compare the relative valuation of stocks to one of the more predictive measures of future stock returns: EPS.

Magic Formula Stock Review: Endo Pharmaceuticals (ENDP)

(via www.magicdiligence.com)

Endo Pharmaceuticals is a highly profitable specialty drug maker specializing in pain killers such as Lidoderm, Opana, and Percocet. While the outlook is very good for the next few years, major patent cliffs and pipeline problems could keep the valuation lower than normal.

Sequoia (Ruane, Cunniff & Goldfarb) files 13F for December 31st, 2009

(via www.rocketfinancial.com)

Sequoia's Q4 portfolio has been filed. New positions include: WSH, ATLS, STRA, ACGL, FSC, AZO, MRK, KMR, CMCSK, LMT, LH, ORCL, APA, MMM, SLB, RHI, TROW, LOW, ADP, VAR, and YBTVA.

JNJ valuation and competetive analysis

(via www.EquityHive.com)

JNJ the best of Pharma

Pharma, the best of

(via www.equithive.com)

the best of pharma - Johnson & Johnson valuation compared against, Celgene, Pfizer, Abbott Laboratories, Merck and Bristol Myers Squibb